drugset / Trial / NCT00228059
An Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine in the Treatment of Manic Episodes of Bipolar I Disorder.
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This extension study is designed to investigate the long-term safety and tolerability of licarbazepine 750-2000 mg/day over 52 weeks in patients who completed the 3-week double-blind study CLIC477D2301.
Timeline
- Start
- 2005-01
- Primary completion
- 2007-07
- Completion
- 2007-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Licarbazepine | Small molecule | 750 mg | — |
| Subject | Licarbazepine | Small molecule | 2000 mg | — |